Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Pharmacology of 5-HT2B
3,4-CTMP acts as a dopamine and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of dopamine and norepinephrine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects.[1] 3,4-CTMP has also been identified as a relatively potent agonist of 5-HT2B serotonin receptors.[2] This is concerning, as agonism of the 5-HT2B receptors results in a potentially serious effect called pulmonary hypertension, where the pulmonary artery that pumps blood from the heart to the lungs constricts. Additionally, chronic stimulation of 5-HT2B receptors has been implicated in serious heart valve disease via fibrosis. Other drugs with this effect, such as aminorex (a pharmaceutical weight loss drug that was pulled from the market), have resulted in a large number of long term heart injuries and fatalities across the world.
The highest dose I have experienced within the same hour is 100mg nasally, which produced noticeable euphoria, but also a raise in heartrate and a longer period of time before sleep was possible.

Forum Jump:

Users browsing this thread: 1 Guest(s)

About Research Chemicals forum

              Quick Links

              User Links